🇺🇸 FDA
Pipeline program

Alirocumab

EFC11570

Phase 3 small_molecule completed

Quick answer

Alirocumab for Atherosclerotic Cardiovascular Disease is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Atherosclerotic Cardiovascular Disease
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials